Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

pSivida eyes key market after wining Chinese patent:

This article was originally published in Clinica

Executive Summary

Australian firm pSivida has gained its first Chinese patent for its drug-delivery product, BrachySil, for primary liver cancer. The Perth-based firm says it is currently in discussions with commercialisation partners for BrachySil in China, which has the highest incidence of primary liver cancer in the world, with 345,800 cases in 2002. It expects to enter into a supply agreement with a local distributor responsible for obtaining regulatory approval, sales and marketing. The Chinese patent - No ZL 99807447.0 - provides protection for silicon implants comprising tissue compatible biodegradable silicon for drug delivery.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT055168

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel